Gemphire Therapeutics Inc. (GEMP) Reaches $5.06 After 8.00% Down Move; Shorts at TECNICAS REUNIDAS SA MADRID ORDINARY SHA (TNISF) Lowered By 0.37%

May 4, 2018 - By Marguerite Chambers

Técnicas Reunidas, S.A. (OTCMKTS:TNISF) Logo

TECNICAS REUNIDAS SA MADRID ORDINARY SHA (OTCMKTS:TNISF) had a decrease of 0.37% in short interest. TNISF’s SI was 487,200 shares in May as released by FINRA. Its down 0.37% from 489,000 shares previously. The SI to TECNICAS REUNIDAS SA MADRID ORDINARY SHA’s float is 1.48%. It closed at $30.59 lastly. It is down 0.00% since May 4, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a huge mover today! The stock decreased 2.22% or $0.115 during the last trading session, reaching $5.055. About 52,273 shares traded. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has declined 45.18% since May 4, 2017 and is downtrending. It has underperformed by 56.73% the S&P500.The move comes after 6 months negative chart setup for the $71.94M company. It was reported on May, 4 by Barchart.com. We have $4.65 PT which if reached, will make NASDAQ:GEMP worth $5.76 million less.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $71.94 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

More recent Gemphire Therapeutics Inc. (NASDAQ:GEMP) news were published by: Nasdaq.com which released: “Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer” on May 03, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Karyopharm’s STORM Study, Inogen Rallies On Earnings” on May 01, 2018. Globenewswire.com‘s news article titled: “Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)” with publication date: April 12, 2018 was also an interesting one.

Analysts await Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report earnings on May, 8. They expect $-0.63 EPS, up 20.25% or $0.16 from last year’s $-0.79 per share. After $-0.63 actual EPS reported by Gemphire Therapeutics Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 3 analysts covering Gemphire Therapeutics (NASDAQ:GEMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gemphire Therapeutics had 3 analyst reports since August 30, 2016 according to SRatingsIntel. The rating was initiated by RBC Capital Markets with “Outperform” on Tuesday, August 30. The rating was initiated by Jefferies on Tuesday, August 30 with “Buy”. The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) earned “Buy” rating by Canaccord Genuity on Tuesday, August 30.

T??cnicas Reunidas, S.A., a general contractor, engages in the engineering, design, and construction of various industrial facilities primarily in refinery, gas, and power sectors worldwide. The company has market cap of $1.76 billion. The firm operates in Oil and Gas, Power, and Infrastructure and Industry divisions. It currently has negative earnings. It creates and manufactures basic refining plants, plant conversions, and octane enhancement projects in the refining sector; chemical plants and fertilizer units, as well as monomers, polymers, and plastics production and processing plants in the petrochemicals sectors; and gas treatment and fractionation plants, and gas and oil pipelines and compressor stations, as well as natural gas, liquefaction, regasification, and storage plants.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>